Abstract:
The results of numerous studies convincingly prove that fenofibrate, by affecting the activity of PPAR receptors, has hypolipidemic, antiinflammatory and antioxidant effects. Activation of PPAR receptors in the liver leads to a decrease in the level of lipids that cause atherosclerosis (VLDL, small dense LDL), and an increase in the level of antiatherogenic HDL. Activation of PPAR-α in vascular cells allows to reduce the activity of inflammatory markers, such as C-reactive protein, tumor necrosis factor-β, interleukin-6, fibrinogen, etc. These advantages ultimately reduce the risk of development and progression of macro- and microvascular complications in diabetes mellitus.This
abstract will review Evidence-based summary of the efficacy of fenofibrate (Tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes.
